Condition category
Nutritional, Metabolic, Endocrine
Date applied
Date assigned
Last edited
Retrospectively registered
Overall trial status
Recruitment status
No longer recruiting
Publication status

Plain English Summary

Background and study aims
There is public concern over the safety of the artificial sweetener aspartame and the European Food Safety Authority has brought together an expert committee to review the evidence. The UK Food Standards Agency has suggested a small study to look at the concerns of the public on the symptoms caused by aspartame. In this study we will use questionnaires and laboratory tests to determine whether the perceived effects of aspartame can be detected in people who say they have a problem eating aspartame, compared with people who consume aspartame with no problem.

Who can participate?
People who say they have a problem eating aspartame and people who normally consume foods containing aspartame with no problem.

What does the study involve?
Participants are asked to eat a snack bar containing aspartame and a matched bar containing no aspartame at two visits one week apart. The dose of aspartame is well below the maximum recommended level.

What are the possible benefits and risks of participating?
Not provided at time of registration.

Where is the study run from?
University of Hull and Hull Royal Infirmary Hospital (UK).

When is the study starting and how long is it expected to run for?
February 2010 to August 2012.

Who is funding the study?
Food Standard Agency (UK).

Who is the main contact?
Professor Stephen Atkin

Trial website

Contact information



Primary contact

Prof Stephen Atkin


Contact details

Hull York Medical School
Michael White Centre for Diabetes
Endocrinology & Metabolism
Brocklehurst Building
Hull Royal Infirmary
220-236 Anlaby Road
United Kingdom
+44 (0)1482 675312

Additional identifiers

EudraCT number number

Protocol/serial number

Version 1.5

Study information

Scientific title

Determination of the symptoms of aspartame in subjects who have reported symptoms in the past compared to controls: a pilot double blind placebo-controlled study


Study hypothesis

To assess the efficacy of the necessary psychometric and biochemical methodologies to determine whether the perceived effects of aspartame can be detected in sufferers compared to non sufferers

Ethics approval

East Yorkshire & North Lincolnshire Research Ethics Committee, 30/06/2009, ref: 09/H1304/46

Study design

Double-blinded placebo-controlled study

Primary study design


Secondary study design

Randomised controlled trial

Trial setting


Trial type


Patient information sheet

Not available in web format, please use the contact details below to request a patient information sheet


Safety study to assess the effect of aspartame


75 self reported responders to aspartame and 75 normal control participants

The snack bar is to be eaten by fasting participants; they will be asked to eat 2 bars given in a double blinded and randomized order, one containing aspartame and one is aspartame free. These bars will be given to the subject one week apart. The dose of aspartame in the bar is 100mg, this is well below the Reference Daily Intake maximum recommended by EFSA of 40mg/kg bw.

Visit 1 - Full blood count (FBC), biochemical profile
Visit 2 & 3 - Insulin, Glucose, Glucagon-like peptide-1 (GLP-1), Gastric inhibitory polypeptide (GIP), biochemical profile and glucose, glucagons, Interleukins, TNF alpha and IgE, Aspartame

Intervention type



Drug names

Primary outcome measure

Testing of the rigour of the study methods and design. To determine the power needed for a large scale study for the investigation of subjects with self diagnosed adverse reactions to aspartame.

Secondary outcome measures

1. To validate that the product used for the trial is optimal and fit for purpose
2. To ascertain the optimal design for the main study
3. To validate the questionnaire tools for the identification of symptoms of adverse events in individuals reporting self diagnosed adverse reactions
4. To validate the biochemical assays in individuals reporting self diagnosed adverse reaction

Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)


Participant inclusion criteria

Healthy volunteers:
1. No known allergies
2. No concomitant medical condition
3. No medication

Aspartame reactors:
1. Reported effect of aspartame on ingestion
2. No allergies to other food substances

Participant type

Healthy volunteer

Age group




Target number of participants

150 (75 normal control / 75 aspartame sensitive)

Participant exclusion criteria

1. Allergies to food or medication
2. A concomitant medical condition
3. Prescription medication
4. Refusal for GP to be informed

Aspartame reactors:
1. Allergies to food or medication
2. A concomitant medical condition
3. Prescription medication
4. Refusal for GP to be informed

Recruitment start date


Recruitment end date



Countries of recruitment

United Kingdom

Trial participating centre

Hull York Medical School
United Kingdom

Sponsor information


Hull and East Yorkshire Hospitals NHS Trust (UK)

Sponsor details

Research & Development Department
2nd Floor
Daisy Building
Castle Hill Hospital
Castle Road
HU16 5JQ
United Kingdom
+44 (0)1482 461903

Sponsor type

Hospital/treatment centre



Funder type


Funder name

Food Standards Agency

Alternative name(s)


Funding Body Type

private sector organisation

Funding Body Subtype

Other non-profit organizations


United Kingdom

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Basic results (scientific)

Publication list

2015 results in:

Publication citations

Additional files

Editorial Notes